ROIV250117P15000
- 4.60
- 0.000.00%
Roivant Sciences Newsroom
Express News | Roivant Sciences Ltd : Guggenheim Cuts Target Price to $15 From $16
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing
Roivant Sciences(ROIV.US) Officer Sells US$4.14 Million in Common Stock
Express News | Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 4.23 Million in Common Stocks
Insider Sale: Pres&Chief Investment Officer of $ROIV (ROIV) Sells 10,796 Shares
Roivant Sciences(ROIV.US) Officer Sells US$10.64 Million in Common Stock
Express News | Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 8.28 Million in Common Stocks
Roivant Sciences(ROIV.US) Officer Sells US$4.97 Million in Common Stock
Five Reasons Why UBS Is Overweight the UK
Express News | Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 4.97 Million in Common Stocks
Roivant Sciences (ROIV) Receives a Buy From Leerink Partners
Optimistic Outlook on Roivant Sciences Despite Namilumab Setback
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Roivant Sciences Ends Namilumab Study Due to Inefficacy
Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study
Express News | Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study
Express News | Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit
Express News | Roivant Sciences Ltd - Kinevant to Discontinue Namilumab Development for Sarcoidosis
Express News | Roivant Announces Topline Results From Phase 2 Resolve-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Roivant Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis